MYOS RENS Technology Inc. (NASDAQ:MYOS) CEO Joseph Mannello bought 11,750 shares of the stock in a transaction on Tuesday, November 14th. The shares were bought at an average cost of $1.27 per share, with a total value of $14,922.50. Following the purchase, the chief executive officer now owns 203,560 shares of the company’s stock, valued at $258,521.20. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Joseph Mannello also recently made the following trade(s):
- On Thursday, November 16th, Joseph Mannello acquired 25,000 shares of MYOS RENS Technology stock. The stock was acquired at an average cost of $1.31 per share, with a total value of $32,750.00.
Shares of MYOS RENS Technology Inc. (NASDAQ MYOS) opened at $1.41 on Tuesday. MYOS RENS Technology Inc. has a 1-year low of $1.02 and a 1-year high of $6.98.
MYOS RENS Technology (NASDAQ:MYOS) last issued its earnings results on Tuesday, November 14th. The company reported ($0.13) earnings per share for the quarter. The firm had revenue of $0.16 million during the quarter. MYOS RENS Technology had a negative net margin of 941.41% and a negative return on equity of 71.14%.
Separately, ValuEngine lowered shares of MYOS RENS Technology from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/12/05/insider-buying-myos-rens-technology-inc-myos-ceo-buys-14922-50-in-stock.html.
About MYOS RENS Technology
MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.